STATE-OF-THE-ART PAPER
Vascular Closure DevicesThe Second Decade
Harold L. Dauerman, MD, FACC*,*,
Robert J. Applegate, MD, FACC and
David J. Cohen, MD, MSc
* Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont
Division of Cardiology, Wake Forest University Medical Center, Winston-Salem, North Carolina
Saint Luke's Mid-America Heart Institute, Kansas City, Missouri
Manuscript received May 3, 2007;
revised manuscript received July 5, 2007,
accepted July 15, 2007.
* Reprint requests and correspondence: Dr. Harold L. Dauerman, University of Vermont College of Medicine, Fletcher Allen Health Care, 111 Colchester Avenue, McClure 1 Cardiology, Burlington, Vermont 05401. (Email: harold.dauerman{at}vtmednet.org).
Vascular closure devices (VCDs) introduce a novel means for improving patient comfort and accelerating ambulation after invasive cardiovascular procedures performed via femoral arterial access. Vascular closure devices have provided simple, rapid, and reliable hemostasis in a variety of clinical settings. Despite more than a decade of development, however, VCD utilization has neither been routine in the U.S. nor around the world. Their limited adoption reflects concerns of higher costs for cardiac procedures and a lack of data confirming a significant reduction in vascular complications compared with manual compression. Recent data, however, suggest that VCD are improving, complication rates associated with their use may be decreasing, and their utilization may improve the process of care after femoral artery access. Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices.
|
Abbreviations and Acronyms
| | PCI = percutaneous coronary intervention | | VCD = vascular closure device |
|
This article has been cited by other articles:

|
 |

|
 |
 
J. B. Lindsey, S. P. Marso, M. Pencina, J. M. Stolker, K. F. Kennedy, C. Rihal, G. Barsness, R. N. Piana, S. L. Goldberg, D. E. Cutlip, et al.
Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients: Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1074 - 1082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ahmed, W. D. Piper, D. Malenka, P. VerLee, J. Robb, T. Ryan, M. Herne, W. Phillips, and H. L. Dauerman
Significantly Improved Vascular Complications Among Women Undergoing Percutaneous Coronary Intervention: A Report From the Northern New England Percutaneous Coronary Intervention Registry
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
423 - 429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Wong, W. Bachinsky, P. Cambier, R. Stoler, J. Aji, J. H. Rogers, J. Hermiller, R. Nair, H. Hutman, H. Wang, et al.
A Randomized Comparison of a Novel Bioabsorbable Vascular Closure Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Femoral Procedures: The ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial)
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
785 - 793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. Dauerman, R. J. Applegate, and D. J. Cohen
Reply
J. Am. Coll. Cardiol.,
April 8, 2008;
51(14):
1417 - 1417.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Phillips and P. Ver Lee
Vascular Closure Devices: Begin With the End in Mind
J. Am. Coll. Cardiol.,
April 8, 2008;
51(14):
1416 - 1417.
[Full Text]
[PDF]
|
 |
|
|